📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-13 20:03
122 analysed today
FollowTelegram
122
Today
149,523
All-time analysed
42,890
Positive
6,652
Negative
91,308
Neutral
8,605
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
9 announcements match the current filters (relevance ≥ 5).
Brooks Labs Q1 FY27: Consolidated Loss of ₹1.79 Cr vs ₹9.58 Cr Profit YoY
Brooks Laboratories reported a weak start to FY27, with consolidated revenue declining 10% YoY to ₹22.96 Cr. The company swung to a consolidated net loss of ₹1.79 Cr, a sharp reversal from the ₹9.58 Cr profit recorded in Q1 FY26. This downturn was primarily caused by a ₹3.21 Cr share of loss from its joint venture, Brooks Steriscience Limited, which reported a total loss of ₹6.54 Cr for the quarter. While standalone operations remained profitable at ₹1.42 Cr, this was still a 46% decline from the previous year's ₹2.65 Cr.
Confidence: HIGH
What changedThe company has transitioned from a highly profitable consolidated position to a net loss, primarily due to its joint venture turning loss-making and a decline in core manufacturing revenue.
Why it mattersThe joint venture was previously a significant profit contributor (contributing ₹18.78 Cr in FY26); its current performance creates a major drag on the consolidated financials of this small-cap firm.
Consolidated Revenue (Q1): ₹22.96 CrConsolidated Net Loss: ₹1.79 CrShare of JV Loss: ₹3.21 CrStandalone Net Profit: ₹1.42 CrRevenue vs TTM Revenue: ~26.7%
📅 Short termThe stock is likely to face downward pressure in the short term as the market reacts to the swing from profit to loss and the decline in top-line growth.
📈 Long termThe long-term outlook depends on the company's ability to stabilize the JV and scale its manufacturing operations in Baddi to reach its ₹100 Cr target; current results show a setback in this trajectory.
⚠ Risk flags
- Significant losses in Joint Venture
- Declining core manufacturing revenue
- High volatility in consolidated earnings
Key Highlights
Consolidated revenue fell 10% YoY to ₹22.96 Cr from ₹25.51 Cr in the year-ago period
Swung to a consolidated net loss of ₹1.79 Cr compared to a profit of ₹9.58 Cr in Q1 FY26
Share of loss from Joint Venture (Brooks Steriscience) stood at ₹3.21 Cr, impacting the bottom line
Standalone net profit declined 46.4% YoY to ₹1.42 Cr from ₹2.65 Cr
Manufacturing segment revenue, the core business, decreased to ₹22.78 Cr from ₹25.15 Cr YoY
👀 What to Watch
Investors should closely monitor the turnaround timeline for the Brooks Steriscience JV, as its losses are currently offsetting standalone profits. Additionally, track the manufacturing segment's margins, which have compressed significantly compared to the previous year.
Rs 106.33 Cr Cash Inflow: Brooks Labs Signs Binding MoU for Stake Sale in JV
Brooks Laboratories has executed a binding MoU to sell a 16.33% stake in its joint venture, Brooks Steriscience Limited (BSL), reducing its holding from 49.00% to 32.67%. The transaction is expected to bring an immediate cash inflow of Rs 106.33 crores, which is substantial given the company's TTM revenue of Rs 86 crores. The agreement includes a value protection framework for the remaining 32.67% stake, valuing it at a minimum of USD 22.87 million. This liquidity event provides significant capital for the company's stated growth and business expansion plans.
Confidence: HIGH
What changedThe company has progressed from a proposed sale (announced June 19, 2026) to a binding Memorandum of Understanding with specific commercial terms and a defined cash inflow amount.
Why it mattersThe cash inflow of Rs 106.33 crores is highly material, representing approximately 123% of the company's TTM revenue and nearly 88% of its net worth. This provides a massive liquidity boost to a small-cap entity for scaling its manufacturing operations.
Expected Cash Inflow: Rs 106.33 croresInflow vs TTM Revenue: 123.6%Stake Reduction: 16.33% (from 49% to 32.67%)Retained Stake Floor Value: USD 22.87 millionMoU Validity: 2 years
📅 Short termThe announcement is likely to be viewed positively by the market due to the significant cash realization and the valuation floor set for the remaining stake.
📈 Long termThe transaction allows Brooks to monetize its JV investment while retaining a significant minority stake. The long-term impact depends on the successful deployment of the Rs 106.33 Cr into its core manufacturing segment to achieve its Rs 100 Cr revenue target for FY26.
⚠ Risk flags
- Execution risk of definitive transaction documents
- Regulatory approval requirements
- Two-year term limit on the value protection framework
Key Highlights
Stake in Brooks Steriscience Limited to be reduced from 49.00% to 32.67% following the transaction.
Immediate cash inflow of approximately Rs 106.33 crores to be utilized for growth and expansion.
Value protection floor for the retained 32.67% stake set at a minimum of USD 22.87 million based on a USD 70 million business valuation.
Future capital requirements for the existing business to be met primarily through debt financing to prevent further dilution.
MoU is binding for a period of two years and includes provisions for the release of corporate guarantees extended by Brooks Labs.
👀 What to Watch
Investors should monitor the execution of definitive transaction documents and the timeline for the actual receipt of the Rs 106.33 crore inflow. The key educational focus is how the company utilizes this cash—whether for high-margin manufacturing expansion or debt reduction—to improve its current ROCE of 5.3%.
Brooks Labs to Sell 16.33% Stake in Brooks Steriscience for ₹106.33 Crore
Brooks Laboratories Limited has approved the partial monetization of its investment in Brooks Steriscience Limited by selling 51,220 equity shares. The sale to Steriscience Specialties Private Limited is priced at ₹20,760 per share, resulting in a total cash consideration of approximately ₹106.33 crore. Following the transaction, Brooks Labs will retain a 32.67% stake, down from its previous 49.00% holding. The company intends to utilize the proceeds for operational expansion, capacity enhancement, and funding new business opportunities.
Key Highlights
Sale of 51,220 equity shares representing a 16.33% stake in Brooks Steriscience Limited.
Total cash consideration of ₹106.33 crore at a valuation of ₹20,760 per share.
Post-transaction shareholding reduced from 49.00% to 32.67%.
Proceeds earmarked for growth strategy, capacity expansion, and general corporate purposes.
The transaction is a non-related party disposal and will be completed in cash.
👀 What to Watch
Investors should view this as a significant value-unlocking event that provides substantial liquidity for growth; monitor the effective deployment of the ₹106 crore cash inflow into core operations.
Brooks Labs to Sell 16.33% Stake in Brooks Steriscience for ₹106.33 Crore
Brooks Laboratories Limited has approved the sale of 51,220 equity shares in Brooks Steriscience Limited to Steriscience Specialities Private Limited. The deal is valued at ₹20,760 per share, resulting in a total cash consideration of approximately ₹106.33 crore. Following this 16.33% stake sale, Brooks Laboratories will continue to hold a significant 32.67% stake in the entity. The company intends to utilize these funds for capacity expansion, growth strategies, and general corporate purposes.
Key Highlights
Sale of 51,220 equity shares at a price of ₹20,760 per share.
Total cash consideration amounting to ₹106.33 crore.
Stake reduction from 49.00% to 32.67%, representing a partial monetization.
Proceeds earmarked for business expansion, capacity enhancement, and funding growth opportunities.
The transaction is not a related party transaction and involves no promoter interest.
👀 What to Watch
Investors should monitor the deployment of the ₹106.33 crore cash inflow into growth projects, as this monetization significantly strengthens the company's liquidity position for expansion.
Brooks Laboratories Appoints CFO Prashant Rathi as CEO Effective June 1, 2026
Brooks Laboratories has announced the appointment of Mr. Prashant Rathi as the Chief Executive Officer, effective June 1, 2026. Mr. Rathi will hold this position in addition to his current role as the Chief Financial Officer (CFO). With over 13 years of experience in finance and 5 years specifically at Brooks Laboratories, the board is leveraging his internal expertise for strategic growth. This internal promotion ensures leadership continuity but consolidates two major executive functions under one individual.
Key Highlights
Mr. Prashant Rathi appointed as CEO effective June 1, 2026, while retaining his CFO position.
The appointee has over 13 years of experience in accounting, finance, and financial management.
Mr. Rathi has been associated with Brooks Laboratories for more than 5 years.
Qualifications include Chartered Accountant (CA), Company Secretary (CS), and a Diploma in IFRS from ACCA, UK.
👀 What to Watch
Investors should monitor the company's operational performance under this consolidated leadership structure and watch for any future plans to appoint a separate CFO to ensure robust corporate governance.
Brooks Labs FY26 Results: CEO Appointment and Diversification Plan Halted
Brooks Laboratories Limited has approved its audited financial results for the quarter and year ended March 31, 2026, with auditors issuing an unmodified opinion. A significant regulatory update confirms that the company's proposed diversification into new business segments was rejected by the Registrar of Companies, forcing the firm to stick to its core pharmaceutical operations. In a major leadership change, current CFO Prashant Rathi has been appointed as the Chief Executive Officer (CEO). The consolidated results include the performance of its jointly controlled entity, Brooks Steriscience Limited.
Key Highlights
Audited Standalone and Consolidated financial results for FY26 approved with an unmodified audit opinion.
Proposed expansion into diversified business segments cancelled after RoC rejected the alteration of the Object Clause.
Prashant Rathi appointed as CEO in addition to his existing role as Chief Financial Officer (CFO).
Company to remain exclusively engaged in the manufacturing and distribution of pharmaceutical products.
Consolidated results incorporate the financial performance of Brooks Steriscience Limited.
👀 What to Watch
Investors should monitor how the consolidation of CEO and CFO roles affects corporate governance and focus on the core pharma business's growth now that diversification is off the table. Review the full financial statements to assess the underlying profitability of the pharmaceutical operations.
Brooks Lab Associate BSL Withdraws from Proposed Merger with Onesource Specialty Pharma
Brooks Laboratories Limited has announced that its associate company, Brooks Steriscience Limited (BSL), will no longer pursue the proposed composite scheme of arrangement and amalgamation in its current form. The scheme, which received in-principle approval from stock exchanges on February 6, 2026, involved multiple entities including Onesource Specialty Pharma and Strides Pharma Services. The BSL Board decided to terminate the transaction after a meeting on May 14, 2026, citing the best interests of stakeholders. This move halts the previously planned consolidation and value-unlocking process for the associate entity.
Key Highlights
BSL Board officially decided not to pursue the merger transaction in its current form on May 14, 2026.
The proposed scheme involved five entities including Steriscience Specialties, BSL, and Onesource Specialty Pharma.
In-principle approval for the merger had been previously secured from NSE and BSE in February 2026.
BSL is a significant Joint Venture / Associate company of Brooks Laboratories Limited.
The cancellation stops a complex multi-party amalgamation process that was expected to impact the company's valuation.
👀 What to Watch
Investors should exercise caution as the cancellation of the merger may lead to short-term volatility and requires a reassessment of the associate company's growth strategy. Monitor for any future announcements regarding a revised scheme or alternative strategic partnerships.
Brooks Labs Associate BSL Receives Stock Exchange NOC for Merger; Board to Review NCLT Filing
Brooks Laboratories Limited has provided an update regarding its associate company, Brooks Steriscience Limited (BSL), which is involved in a complex composite scheme of arrangement and amalgamation. BSL has received No-objection/No Adverse Observation Letters from both the NSE and BSE, marking a significant regulatory milestone. However, the BSL Board has decided to conduct a further review of the scheme before proceeding with the formal application to the National Company Law Tribunal (NCLT). This review is slated to be completed within the six-month validity period of the stock exchange approvals.
Key Highlights
BSL received No-objection letters from NSE and BSE for the proposed composite scheme of arrangement.
The stock exchange approvals are valid for a period of 6 months from the date of issue.
The scheme involves multiple entities including OneSource Specialty Pharma and Strides Pharma Services.
BSL Board has opted for a further internal review before filing the NCLT application.
The review process is expected to be finalized within the current six-month approval window.
👀 What to Watch
Investors should track the progress of the BSL board's review and the subsequent NCLT filing, as this merger is a key value driver for Brooks' investment in the associate. The delay for 'further review' warrants a cautious watch on the final terms or potential adjustments to the scheme.
Brooks Labs Q3 Cons. PAT at ₹5.50 Cr; YoY Turnaround from Loss
Brooks Laboratories reported a consolidated net profit of ₹5.50 crore for Q3 FY26, marking a significant recovery from a loss of ₹2.13 crore in the previous year's corresponding quarter. This turnaround is largely attributed to a ₹5.20 crore profit contribution from its joint venture, Brooks Steriscience Limited. On a standalone basis, performance was subdued with revenue falling 19% YoY to ₹16.57 crore and net profit dropping to ₹0.30 crore. The company also faced a regulatory setback as the RoC did not approve the alteration of its Object Clause.
Key Highlights
Consolidated Net Profit of ₹5.50 crore in Q3 FY26 vs a loss of ₹2.13 crore in Q3 FY25
Joint venture Brooks Steriscience contributed ₹5.20 crore to the quarterly profit
Standalone Revenue declined 19.2% YoY to ₹16.57 crore from ₹20.52 crore
Nine-month consolidated profit stands at ₹23.06 crore compared to a loss of ₹8.51 crore last year
Regulatory rejection of Form MGT-14 prevents the planned alteration of the Memorandum of Association
👀 What to Watch
While the consolidated turnaround is positive, the weakness in the core standalone business and the regulatory hurdle regarding the MoA amendment are concerns. Investors should monitor if the joint venture's profitability can consistently offset standalone sluggishness.
